Oncology Conference update

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Prof. Shaheenah Dawood

Prof. Shaheenah Dawood
Publication Date

Jun 2024

download Downloadable resources

In this conference update video, Prof. Shaheenah Dawood joins us from ASCO 2024 to share her insights into new key breast cancer trial data from the DESTINY-Breast06, postMONARCH and INAVO120 trials and the potential impact on clinical practice.

 

ASCO 2024 selected breast cancer abstracts

  • Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: Primary results from DESTINY-Breast06 (DB-06).
    Curigliano G, et al.
    Abstract LBA1000, ASCO 2024
  • Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
    Kalinsky K, et al.
    Abstract LBA1001, ASCO 2024
  • First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: INAVO120 Phase 3 randomized trial additional analyses.
    Juric D, et al.
    Abstract #1003, ASCO 2024

 

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma
Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Watch the video now
Other episodes of this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO
ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

 Current Episode
ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?
ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024
Share this programme
x-twitter
Supporter Acknowledgement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

video
Oncology 
The latest developments in BRAF-mutant and MSI-H CRC

Expert insights on recent clinical and real-world data

Experts
Prof. Chiara Cremolini
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2025
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
publication Scientific Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025
PRECISION ONCOLOGY CONNECT SARCOMA CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025
GI CONNECT GI NURSES CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
Explore all programmes